Study of the Sars-Cov2 Neuroinvasiveness - COVID19

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04427254

Acronym

CORONEVRAXE

Enrollment

Registered

2020-06-11

Start date

2020-06-26

Completion date

2022-11-25

Last updated

2023-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID19

Keywords

Sars-Cov2 neuroinvasiveness, COVID-19 RT-PCR test

Brief summary

Sars-Cov2 (COVID-19) may invade the CNS inducing neurological diseases such as anosmia, ageusia, encephalitis, ischemic or hemorrhagic stroke. Management of severe neurological complications in COVID-19 patients may require ventricular cerebrospinal fluid drainage and cranial decompression. During surgery, cerebrospinal fluid, meninges and brain parenchyma can be safely removed from the patient. In this study, COVID-19 patients will be evaluated first, for the presence of Sars-Cov2 in the cerebrospinal fluid and/or biopsies and second, for the consequences of Sars-Cov2 neuroinfection in terms of inflammatory and immune responses.

Interventions

DRUGCerebrospinal fluid sampling, meningeal and brain parenchyma biopsies

Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* COVID-19 patients requiring an external ventricular drain, a decompressive craniectomy or an intracranial hematoma surgery

Exclusion criteria

* Pregnant or lactating women

Design outcomes

Primary

Measure	Time frame	Description
Percentage of patients with COVID-19 positive samples/biopsies	At the time of the inclusion	COVID-19 RT-PCR test

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026